Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor δ Agonist

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 27; no. 2; pp. 359 - 365
• Main Authors: Sprecher, Dennis L., Massien, Christine, Pearce, Greg, Billin, Andrew N., Perlstein, Itay, Willson, Timothy M., Hassall, David G., Ancellin, Nicolas, Patterson, Scott D., Lobe, David C., Johnson, Tony G.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Heart Association, Inc 01.02.2007; Hagerstown, MD Lippincott
• Subjects: Adult; Atherosclerosis (general aspects, experimental research); ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters - genetics; ATP-Binding Cassette Transporters - metabolism; Biological and medical sciences; Blood and lymphatic vessels; Blood coagulation. Blood cells; Cardiology. Vascular system; Cardiovascular system; CD36 Antigens - genetics; CD36 Antigens - metabolism; Cells, Cultured; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Fatty Acids - metabolism; Fundamental and applied biological sciences. Psychology; Humans; Lipoproteins, HDL - metabolism; Male; Medical sciences; Molecular and cellular biology; Muscle, Skeletal - cytology; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Oxidation-Reduction - drug effects; Pharmacology. Drug treatments; Platelet; PPAR delta - agonists; PPAR delta - genetics; PPAR delta - metabolism; Thiazoles - pharmacology; Triglycerides - metabolism; Up-Regulation - drug effects; Vasodilator agents. Cerebral vasodilators; Vascular disease; Human; PPAR; Atherosclerosis; Lipids; Cardiovascular disease; Lipoprotein; Triglyceride; lipid; Cholesterol; Peroxisome proliferator
• ISSN: 1079-5642; 1524-4636; 1524-4636
• DOI: 10.1161/01.ATV.0000252790.70572.0c

OBJECTIVES—Exercise increases fatty acid oxidation (FAO), improves serum high density lipoprotein cholesterol (HDLc) and triglycerides (TG), and upregulates skeletal muscle peroxisome proliferator activated receptor (PPAR)δ expression. In parallel, PPARδ agonist-upregulated FAO would induce fatty-acid uptake (via peripheral lipolysis), and influence HDLc and TG-rich lipoprotein particle metabolism, as suggested in preclinical models. METHODS AND RESULTS—Healthy volunteers were allocated placebo (n=6) or PPARδ agonist (GW501516) at 2.5 mg (n=9) or 10 mg (n=9), orally, once-daily for 2 weeks while hospitalized and sedentary. Standard lipid/lipoproteins were measured and in vivo fat feeding studies were conducted. Human skeletal muscle cells were treated with GW501516 in vitro and evaluated for lipid-related gene expression and FAO. Serum TG trended downwards (P=0.08, 10 mg), whereas TG clearance post fat-feeding improved with drug (P=0.02). HDLc was enhanced in both treatment groups (2.5 mg P=0.004, 10 mg P<0.001) when compared with the decrease in the placebo group (−11.5±1.6%, P=0.002). These findings complimented in vitro cell culture results whereby GW501516 induced FAO and upregulated CPT1 and CD36 expression, in addition to a 2-fold increase in ABCA1 (P=0.002). However, LpL expression remained unchanged. CONCLUSIONS—This is the first report of a PPARδ agonist administered to man. In this small study, GW501516 significantly influenced HDLc and TGs in healthy volunteers. Enhanced in vivo serum fat clearance, and the first demonstrated in vitro upregulation in human skeletal muscle fat utilization and ABCA1 expression, suggests peripheral fat utilization and lipidation as potential mechanisms toward these HDL:TG effects.